BRPI0614455A2 - efavirenz amorfo e a produção deste - Google Patents

efavirenz amorfo e a produção deste Download PDF

Info

Publication number
BRPI0614455A2
BRPI0614455A2 BRPI0614455-1A BRPI0614455A BRPI0614455A2 BR PI0614455 A2 BRPI0614455 A2 BR PI0614455A2 BR PI0614455 A BRPI0614455 A BR PI0614455A BR PI0614455 A2 BRPI0614455 A2 BR PI0614455A2
Authority
BR
Brazil
Prior art keywords
efavirenz
solvent
composition
polymer
amorphous
Prior art date
Application number
BRPI0614455-1A
Other languages
English (en)
Portuguese (pt)
Inventor
John Alfred Doney
Original Assignee
Isp Investments Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isp Investments Inc filed Critical Isp Investments Inc
Publication of BRPI0614455A2 publication Critical patent/BRPI0614455A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Glanulating (AREA)
  • Vaporization, Distillation, Condensation, Sublimation, And Cold Traps (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0614455-1A 2005-07-28 2006-07-28 efavirenz amorfo e a produção deste BRPI0614455A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70337405P 2005-07-28 2005-07-28
US60/703.374 2005-07-28
PCT/US2006/029822 WO2007014393A2 (en) 2005-07-28 2006-07-28 Amorphous efavirenz and the production thereof

Publications (1)

Publication Number Publication Date
BRPI0614455A2 true BRPI0614455A2 (pt) 2011-03-29

Family

ID=37450928

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0614455-1A BRPI0614455A2 (pt) 2005-07-28 2006-07-28 efavirenz amorfo e a produção deste

Country Status (6)

Country Link
US (2) US20070026073A1 (https=)
EP (2) EP1909762A2 (https=)
JP (2) JP2009502969A (https=)
CN (3) CN101272769B (https=)
BR (1) BRPI0614455A2 (https=)
WO (2) WO2007014393A2 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
WO2008062908A1 (en) * 2006-11-24 2008-05-29 Canon Kabushiki Kaisha Method for producing particles and particles
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
CL2008000746A1 (es) * 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
ITMI20071502A1 (it) * 2007-07-25 2009-01-26 Archimica Srl Procedimento per la preparazione di formulazioni solide a rilascio controllato contenenti oxcarbazepina e formulazioni ottenibili con tale procedimento
ITMI20080807A1 (it) 2008-05-05 2009-11-06 Antibioticos Spa Procedimento per la preparazione di tigeciclina in forma amorfa
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
BRPI0919249B1 (pt) * 2008-09-25 2017-12-19 Isp Investments Inc. Coating composition, method for coating solids and coated product
US11458105B2 (en) 2008-12-04 2022-10-04 International Flavors & Fragrances Inc. Hybrid fragrance encapsulate formulation and method for using the same
ES2718614T3 (es) * 2008-12-10 2019-07-03 Cipla Ltd Complejos de rifaximina
KR20110098849A (ko) 2008-12-23 2011-09-01 파마셋 인코포레이티드 뉴클레오시드 유사체
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
PT2376088T (pt) 2008-12-23 2017-05-02 Gilead Pharmasset Llc Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
EP2343056A1 (en) * 2009-12-30 2011-07-13 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Producing stable adefovir dipivoxil solid dispersions
JP2011153119A (ja) * 2010-01-27 2011-08-11 Mylan Seiyaku Ltd バンコマイシンまたはその塩を含有する錠剤
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
WO2012063498A2 (ja) * 2010-11-12 2012-05-18 富士化学工業株式会社 新規なエキセメスタン固体分散体
AU2011332031B2 (en) 2010-11-24 2017-01-12 Melinta Subsidiary Corp. Pharmaceutical compositions
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
CN103429228B (zh) 2011-01-05 2016-10-26 赫士睿股份有限公司 万古霉素的喷雾干燥
GB201115633D0 (en) * 2011-09-09 2011-10-26 Univ Liverpool Compositions of efavirenz
WO2014043208A1 (en) 2012-09-11 2014-03-20 Medivation Prostate Therapeutics, Inc. Formulations of enzalutamide
US9114170B2 (en) 2012-11-08 2015-08-25 Isp Investments Inc. Highly loaded amorphous efavirenz composition and process for preparing the same
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
CN104119209B (zh) * 2013-04-25 2018-03-02 浙江医药股份有限公司新昌制药厂 一种还原型辅酶q10干粉及其组合物以及制备方法
US9951009B2 (en) * 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
US20160287568A1 (en) * 2013-11-22 2016-10-06 Merck Sharp & Dohme Corp. Composition of a non-nucleoside reverse transcriptase inhibitor
BR112016012912A8 (pt) * 2013-12-04 2018-01-30 Hovione Scientia Ltd formulações de meios de contraste com dissimulação de sabor
CA2941632C (en) * 2014-03-13 2023-10-24 Vasilios VOUDOURIS Bendamustine solid dispersions and continuous infusion
PT107568B (pt) * 2014-03-31 2018-11-05 Hovione Farm S A Processo de secagem por atomização para a produção de pós com propriedades melhoradas.
CN105853482A (zh) * 2015-01-21 2016-08-17 熊慧 人参总次苷在制备治疗和/或预防心肌缺血后脂质代谢异常的药物中的应用
EP3103440A1 (en) 2015-06-12 2016-12-14 INDENA S.p.A. Solid dispersions of coenzyme q10
AU2018218261B2 (en) * 2017-02-09 2020-06-11 Med-El Elektromedizinische Geraete Gmbh Dexamethasone coating for use with electrode carrier
AU2018218259B2 (en) * 2017-02-09 2019-12-12 Med-El Elektromedizinische Geraete Gmbh Implantable electrode with dexamethasone coating
WO2020002595A1 (en) * 2018-06-29 2020-01-02 Dsm Ip Assets B.V. Fast release benzoic acid in feed
CN114404377B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法
WO2024092404A1 (zh) * 2022-10-31 2024-05-10 南京百正生物医药有限公司 哌拉西林他唑巴坦喷雾干燥粉末的工业化生产方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1418001A (fr) * 1962-08-13 1965-11-19 Du Pont Procédé de préparation d'explosifs cristallins de grande puissance
GB1201171A (en) * 1967-03-28 1970-08-05 Atomic Energy Authority Uk Improvements in or relating to the production of fine powders
US3981676A (en) * 1970-03-03 1976-09-21 L'oreal Lyophilized dyes and the use thereof to color keratinic fibers
DE2223896A1 (de) * 1972-05-17 1973-11-29 Sanol Arznei Schwarz Gmbh Verfahren zum ueberziehen von feinteiligen arzneimitteln
JPS5313346B2 (https=) * 1974-03-20 1978-05-09
US4956386A (en) 1980-04-25 1990-09-11 Gist-Brocades N.V. Pharmaceutical compositions and process for their preparation
JPS5836628A (ja) * 1981-08-26 1983-03-03 Ngk Spark Plug Co Ltd 無機質粉体の造粒方法
US4572915A (en) 1984-05-01 1986-02-25 Bioglan Laboratories Clear micellized solutions of fat soluble essential nutrients
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IT1263840B (it) * 1993-03-30 1996-09-04 Giuseppe Furiosi Formulazioni orali di ubidecarenone in forma di capsule
DE4327063A1 (de) * 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
EP0804249A2 (en) * 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
ES2237767T3 (es) 1995-04-14 2005-08-01 Nektar Therapeutics Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
EP0862420A4 (en) 1995-10-13 1999-11-03 Penn State Res Found SYNTHESIS OF DRUG SPRAY DRUG NANOPARTICLES
IL117773A (en) 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
US6056971A (en) * 1996-07-24 2000-05-02 Biosytes Usa, Inc. Method for enhancing dissolution properties of relatively insoluble dietary supplements and product incorporating same
JP3889481B2 (ja) * 1996-08-16 2007-03-07 株式会社カネカ 医薬組成物
IT1284604B1 (it) 1996-09-27 1998-05-21 Roberto Valducci Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
EP0913177A1 (de) * 1997-11-03 1999-05-06 Roche Diagnostics GmbH Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9819272D0 (en) 1998-09-03 1998-10-28 Andaris Ltd Microparticles
JP2002534371A (ja) 1999-01-06 2002-10-15 コリア リサーチ インスティテュート オブ ケミカル テクノロジー 水不溶性薬物を含む医薬的活性成分の製造方法及びそれを含む経口投与用医薬組成物
ES2306646T3 (es) 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB9919693D0 (en) 1999-08-19 1999-10-20 Rhone Poulenc Rorer Ltd Process
GEP20053427B (en) 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
US6740338B1 (en) * 2000-01-20 2004-05-25 Raj K. Chopra Reduced form of Cenzyme Q in high bioavailability stable oral dosage form
GB0008411D0 (en) 2000-04-05 2000-05-24 Vectura Ltd Pharmaceutical preparations and their manufacture
AU2001280597A1 (en) * 2000-07-17 2002-01-30 Guilford Pharmaceuticals Inc. Compositions for sustained release of analgesic agents, and methods of making and using the same
US6579521B2 (en) 2000-10-20 2003-06-17 Chiron Corporation Methods of therapy for HIV infection
US6403116B1 (en) * 2000-11-03 2002-06-11 Triarco Inductries, Inc. Coenzyme Q10 formulation
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6300377B1 (en) 2001-02-22 2001-10-09 Raj K. Chopra Coenzyme Q products exhibiting high dissolution qualities
EP1381358B1 (en) * 2001-04-02 2006-05-03 Astrazeneca AB Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
KR100463167B1 (ko) * 2001-04-13 2004-12-23 주식회사 태평양 고분자 나노입자를 이용한 경피흡수제 및 이를 함유한외용제 조성물
AU2002309172A1 (en) * 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
WO2003000235A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
ES2284871T3 (es) 2001-06-22 2007-11-16 Pfizer Products Inc. Composiciones farmaceuticas que contienen una dispersion solida de farmaco poco soluble y un polimero potenciador de la solubilidad.
US20030044474A1 (en) 2001-08-03 2003-03-06 Shaklee Corporation High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
EP1423175B1 (en) * 2001-08-08 2013-10-02 Brown University Research Foundation Methods for micronization of hydrophobic drugs
US6723359B2 (en) * 2001-10-18 2004-04-20 Firmenich Sa Spray-dried compositions and method for their preparation
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
US20030124186A1 (en) * 2001-11-27 2003-07-03 Hussain Munir A. Efavirenz tablet formulation having unique biopharmaceutical characteristics
CA2469718A1 (en) * 2001-12-10 2003-06-19 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
PL371593A1 (en) 2002-02-01 2005-06-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
MXPA04007428A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido.
EP1469833B1 (en) * 2002-02-01 2021-05-19 Bend Research, Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
AU2003205738A1 (en) * 2002-02-14 2003-09-04 Dsm Ip Assets B.V. Water-dispersible coenzyme q10 dry powders
DE10214031A1 (de) * 2002-03-27 2004-02-19 Pharmatech Gmbh Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation
EP1569620A4 (en) * 2002-10-30 2006-03-22 Spherics Inc NANOPARTICULAR BIOACTIVE AGENTS
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
MXPA05011343A (es) * 2003-05-08 2005-12-12 Nektar Therapeutics Uk Ltd Materiales particulados.
CA2523475C (en) 2003-05-28 2013-02-05 Nektar Therapeutics Pharmaceutical formulation comprising a water-insoluble active agent
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050096365A1 (en) 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US20050133949A1 (en) 2003-12-19 2005-06-23 Pragtech, Inc. Polymer solidification and coating process
CA2601762A1 (en) 2005-02-03 2006-08-10 Pfizer Products Inc. Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
WO2006134610A1 (en) 2005-06-16 2006-12-21 Hetero Drugs Limited Efavirenz pharmaceutical composition having enhanced dissolution profile
US20090220596A1 (en) * 2005-07-05 2009-09-03 Abbott Gmbh & Co. Kg Composition and Dosage Form Comprising a Solid or Semi-Solid Matrix
PL1912626T3 (pl) * 2005-08-08 2016-10-31 Postaci użytkowe o polepszonej biodostępności
PL1978936T3 (pl) * 2006-02-03 2013-11-29 Evonik Roehm Gmbh Kompozycje farmaceutyczne zawierające mieszaniny polimerów i trudno rozpuszczalnych w wodzie substancji czynnych
US20190083399A9 (en) * 2006-04-03 2019-03-21 Isa Odidi Drug delivery composition

Also Published As

Publication number Publication date
CN101272848B (zh) 2013-03-13
US10532028B2 (en) 2020-01-14
WO2007016435A2 (en) 2007-02-08
JP2009502487A (ja) 2009-01-29
EP1912730A2 (en) 2008-04-23
CN101272848A (zh) 2008-09-24
WO2007014393A3 (en) 2007-05-31
WO2007016435A3 (en) 2008-02-14
CN101277682A (zh) 2008-10-01
CN101272769A (zh) 2008-09-24
US20070026083A1 (en) 2007-02-01
CN101272769B (zh) 2013-04-24
US20070026073A1 (en) 2007-02-01
CN101277682B (zh) 2015-07-29
JP5243247B2 (ja) 2013-07-24
WO2007014393A2 (en) 2007-02-01
EP1909762A2 (en) 2008-04-16
JP2009502969A (ja) 2009-01-29

Similar Documents

Publication Publication Date Title
BRPI0614455A2 (pt) efavirenz amorfo e a produção deste
Huang et al. Effects of the preparation process on the properties of amorphous solid dispersions
Kaushik et al. An overview on recent patents and technologies on solid dispersion
Sharma et al. Solubility enhancement—eminent role in poorly soluble drugs
Sharma et al. Solid dispersion: A promising technique to enhance solubility of poorly water soluble drug
Leuner et al. Improving drug solubility for oral delivery using solid dispersions
Patil et al. A review-Solubility enhancement of poorly water soluble drugs
US20080152717A1 (en) Amorphous valsartan and the production thereof
WO2008063766A2 (en) Amorphous ezetimibe and the production thereof
US20080181960A1 (en) Carotenoids of enhanced bioavailability
JP5426165B2 (ja) 優れた生物学的利用能のベンゾキノン類
Kalpana et al. Solid Dispersion: Approaches, Technology involved, Unmet need & Challenges.
PT2029110E (pt) Processo para preparar formulações secas por atomização de tmc125
US20080181961A1 (en) Amorphous oxcarbazepine and the production thereof
JPWO2006118210A1 (ja) ジヒドロピリジン系化合物の分解を防止する方法
Kondo et al. Solventless amorphization and pelletization using a high shear granulator. Part II; Preparation of co-amorphous mixture-layered pellets using indomethacin and arginine
Joy et al. Tool to increase solubility: solid dispersion
Mahale et al. Formulation and Characterization of Inclusion Complexes: A Review
Kumar et al. A review on solid dispersion and its application
Joshi et al. Solid Dispersion: A Technology for the Improvement of Oral Bioavailability of Poorly Soluble Drugs
SAHARAN et al. FORMULATION, characterization and in-vitro evaluation of floating microsphere of ibuprofen using carbopol 940 polymer
Giri et al. Carriers used for the development of solid dispersion for poorly water-soluble drugs
Reena Solid dispersion: a fruitful approach for improving the solubility and dissolution rate of poorly soluble drugs
CZ2018234A3 (cs) Zvýšení rozpustnosti a biodostupnosti enzalutamidu
Padwal et al. A REVIEW ON INCLUSION COMPLEXES FORMULATION AND CHARACTERISATION

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.